Imetelstat

Molecular mass: 4,610.18 g/mol  PubChem compound: 72941969

Therapeutic indications

Imetelstat is indicated for:

Low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia

Population group: only adults (18 years old or older)

Imetelstat is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Imetelstat is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.